Gel-mediated delivery of AAV1 vectors corrects ventilatory function in pompe mice with established disease

Molecular Therapy

Volumn 18, Issue 3, 2010, Pages 502-510

  Mah, Cathryn S ^a,b   Falk, Darin J ^a,b   Germain, Sean A ^a,b   Kelley, Jeffry S ^a,b   Lewis, Melissa A ^a,b   Cloutier, Denise A ^a,b   Deruisseau, Lara R ^c   Conlon, Thomas J ^a,b   Cresawn, Kerry O ^a,b   Fraites Jr, Thomas J ^a,b   Campbell Thompson, Martha ^b   Fuller, David D ^a   Byrne, Barry J ^a,b  

^a UNIVERSITY OF FLORIDA   (United States)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^c University of Florida College of Veterinary Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA GLUCOSIDASE; CARBON DIOXIDE; PARVOVIRUS VECTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIAPHRAGM MUSCLE; EXHALATION; FEMALE; GEL; GLYCOGEN STORAGE DISEASE TYPE 2; INHALATION; LUNG VENTILATION; MALE; MOUSE; MUSCLE CONTRACTION; MUSCULAR DYSTROPHY; NONHUMAN; OUTCOME ASSESSMENT; TIDAL VOLUME; VIRAL GENE DELIVERY SYSTEM; VIRUS RECOMBINANT; VIRUS STRAIN;

ANIMALS; CARBON DIOXIDE; DEPENDOVIRUS; DISEASE PROGRESSION; GELS; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; GLYCOGEN STORAGE DISEASE TYPE II; MICE; MICE, TRANSGENIC; MUSCLE CONTRACTION; MUSCULAR DYSTROPHIES; RESPIRATION; TIME FACTORS;

ADENO-ASSOCIATED VIRUS; MUS;

EID: 77649271590     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2009.305     Document Type: Article

References (48)

1. Hirschhorn, R and Reuser, AJJ (2001). Glycogen storage disease type II: acid α-glucosidase (acid maltase) defciency. In: Scriver CR, Beaudet A, Sly WS, Valle D (eds). The Metabolic and Molecular Bases of Inherited Disease. McGraw-Hill: New York, pp 3389-3420.
2. Baudhuin, P, Hers, HG and Loeb, H (1964). An electron microscopic and biochemical study of type II glycogenosis. Lab Invest 13: 1139-1152.
3. Kessler, PD, Podsakoff, GM, Chen, X, McQuiston, SA, Colosi, PC, Matelis, LA et al. (1996). Gene delivery to skeletal muscle results in sustained expression and systemic delivery of a therapeutic protein. Proc Natl Acad Sci USA 93: 14082-14087.
4. Hagemans, ML, van Schie, S P, Janssens, AC, van Doorn, PA, Reuser, AJ and van der Ploeg, AT (2007). Fatigue: an important feature of late-onset Pompe disease. J Neurol 254: 941-945.
5. Raben, N, Plotz, P and Byrne, BJ (2002). Acid α-glucosidase defciency (glycogenosis type II, Pompe disease. Curr Mol Med 2: 145-166.
6. Reuser, AJ, Kroos, MA, Hermans, MM, Bijvoet, AG, Verbeet, MP, Van Diggelen, OP et al. (1995). Glycogenosis type II (acid maltase defciency). Muscle Nerve 3: S61-S69.
7. Kishnani, PS, Corzo, D, Nicolino, M, Byrne, B, Mandel, H, Hwu, WL et al. (2007). Recombinant human acid α-glucosidase: major clinical benefts in infantile-onset Pompe disease. Neurology 68: 99-109.
8. Lachmann, RH (2004). α-Glucosidase (CHO) (Genzyme). Curr Opin Investig Drugs 5: 1101-1110.
9. Cresawn, KO, Fraites, TJ, Wasserfall, C, Atkinson, M, Lewis, M, Porvasnik, S et al. (2005). Impact of humoral immune response on distribution and effcacy of recombinant adeno-associated virus-derived acid α-glucosidase in a model of glycogen storage disease type II. Hum Gene Ther 16: 68-80.
10. Fraites, TJ Jr, Schleissing, MR, Shanely, RA, Walter, GA, Cloutier, DA, Zolotukhin, I et al. (2002). Correction of the enzymatic and functional defcits in a model of Pompe disease using adeno-associated virus vectors. Mol Ther 5(5 Pt 1): 571-578.
11. Mah, C, Fraites, TJ Jr, Cresawn, KO, Zolotukhin, I, Lewis, MA and Byrne, BJ (2004). A new method for recombinant adeno-associated virus vector delivery to murine diaphragm. Mol Ther 9: 458-463.
12. Mah, C, Cresawn, KO, Fraites, TJ Jr, Pacak, CA, Lewis, MA, Zolotukhin, I et al. (2005). Sustained correction of glycogen storage disease type II using adeno-associated virus serotype 1 vectors. Gene Ther 12: 1405-1409.
13. Mah, C, Pacak, CA, Cresawn, KO, Deruisseau, LR, Germain, S, Lewis, MA et al. (2007). Physiological correction of Pompe disease by systemic delivery of adeno-associated virus serotype 1 vectors. Mol Ther 15: 501-507.
14. Rucker, M, Fraites, TJ Jr, Porvasnik, SL, Lewis, MA, Zolotukhin, I, Cloutier, DA et al. (2004). Rescue of enzyme defciency in embryonic diaphragm in a mouse model of metabolic myopathy: Pompe disease. Development 131: 3007-3019.
15. Sun, B, Zhang, H, Franco, LM, Brown, T, Bird, A, Schneider, A et al. (2005). Correction of glycogen storage disease type II by an adeno-associated virus vector containing a muscle-specifc promoter. Mol Ther 11: 889-898. (Pubitemid 40724107)
16. Sun, B, Young, SP, Li, P, Di, C, Brown, T, Salva, MZ et al. (2008). Correction of multiple striated muscles in murine pompe disease through adeno-associated virus-mediated gene therapy. Mol Ther 16: 1366-1371.
17. Ziegler, RJ, Bercury, SD, Fidler, J, Zhao, MA, Foley, J, Taksir, TV et al. (2008). Ability of adeno-associated virus serotype 8-mediated hepatic expression of acid α-glucosidase to correct the biochemical and motor function defcits of presymptomatic and symptomatic Pompe mice. Hum Gene Ther 19: 609-621.
18. Berns, KI and Giraud, C (1996). Biology of adeno-associated virus. Curr Top Microbiol Immunol 218: 1-23.
19. Gao, G, Vandenberghe, LH and Wilson, JM (2005). New recombinant serotypes of AAV vectors. Curr Gene Ther 5: 285-297.
20. Rutledge, EA, Halbert, CL and Russell, DW (1998). Infectious clones and vectors derived from adeno-associated virus (AAV) serotypes other than AAV type 2. J Virol 72: 309-319.
21. Zolotukhin, S, Potter, M, Zolotukhin, I, Sakai, Y, Loiler, S, Fraites, TJ Jr et al. (2002). Production and purifcation of serotype 1, 2, and 5 recombinant adeno-associated viral vectors. Methods 28: 158-167. (Pubitemid 35341079)
22. Zincarelli, C, Soltys, S, Rengo, G and Rabinowitz, JE (2008). Analysis of AAV serotypes 1-9 mediated gene expression and tropism in mice after systemic injection. Mol Ther 16: 1073-1080.
23. Chao, H, Monahan, PE, Liu, Y, Samulski, RJ and Walsh, CE (2001). Sustained and complete phenotype correction of hemophilia B mice following intramuscular injection of AAV1 serotype vectors. Mol Ther 4: 217-222. (Pubitemid 32851285)
24. Xiao, W, Chirmule, N, Berta, SC, McCullough, B, Gao, G and Wilson, JM (1999). Gene therapy vectors based on adeno-associated virus type 1. J Virol 73: 3994-4003.
25. DeRuisseau, LR, Fuller, DD, Qiu, K, DeRuisseau, KC, Donnelly, WH Jr, Mah, C et al. (2009). Neural defcits contribute to respiratory insuffciency in Pompe disease. Proc Natl Acad Sci USA 106: 9419-9424.
26. Petrof, BJ, Acsadi, G, Jani, A, Massie, B, Bourdon, J, Matusiewicz, N et al. (1995). Effciency and functional consequences of adenovirus-mediated in vivo gene transfer to normal and dystrophic (mdx) mouse diaphragm. Am J Respir Cell Mol Biol 13: 508-517.
27. Petrof, BJ, Acsadi, G, Bourdon, J, Matusiewicz, N and Yang, L (1996). Phenotypic and immunologic factors affecting plasmid-mediated in vivo gene transfer to rat diaphragm. Am J Physiol 270(6 Pt 1): L1023-L1030.
28. Yang, L, Lochmuller, H, Luo, J, Massie, B, Nalbantoglu, J, Karpati, G et al. (1998). Adenovirus-mediated dystrophin minigene transfer improves muscle strength in adult dystrophic (MDX) mice. Gene Ther 5: 369-379.
29. Gregorevic, P, Blankinship, MJ, Allen, JM, Crawford, RW, Meuse, L, Miller, DG et al. (2004). Systemic delivery of genes to striated muscles using adeno-associated viral vectors. Nat Med 10: 828-834.
30. Koppanati, BM, Li, J, Xiao, X and Clemens, PR (2009). Systemic delivery of AAV8 in utero results in gene expression in diaphragm and limb muscle: treatment implications for muscle disorders. Gene Ther 16: 1130-1137.
31. Wu, Z, Miller, E, Agbandje-McKenna, M and Samulski, RJ (2006). α2,3 and α2,6 N-linked sialic acids facilitate effcient binding and transduction by adeno-associated virus types 1 and 6. J Virol 80: 9093-9103.
32. Yan, Z, Lei-Butters, DC, Liu, X, Zhang, Y, Zhang, L, Luo, M et al. (2006). Unique biologic properties of recombinant AAV1 transduction in polarized human airway epithelia. J Biol Chem 281: 29684-29692.
33. Ding, E, Hu, H, Hodges, BL, Migone, F, Serra, D, Xu, F et al. (2002). Effcacy of gene therapy for a prototypical lysosomal storage disease (GSD-II) is critically dependent on vector dose, transgene promoter, and the tissues targeted for vector transduction. Mol Ther 5: 436-446.
34. Martin-Touaux, E, Puech, J P, Château, D, Emiliani, C, Kremer, EJ, Raben, N et al. (2002). Muscle as a putative producer of acid α-glucosidase for glycogenosis type II gene therapy. Hum Mol Genet 11: 1637-1645.
35. Fukuda, T, Roberts, A, Plotz, PH and Raben, N (2007). Acid α-glucosidase defciency (Pompe disease). Curr Neurol Neurosci Rep 7: 71-77.
36. Kelly, ME, Zhuo, J, Bharadwaj, AS and Chao, H (2009). Induction of immune tolerance to FIX following muscular AAV gene transfer is AAV-dose/FIX-level dependent. Mol Ther 17: 857-863.
37. Xin, KQ, Mizukami, H, Urabe, M, Toda, Y, Shinoda, K, Yoshida, A et al. (2006). Induction of robust immune responses against human immunodefciency virus is supported by the inherent tropism of adeno-associated virus type 5 for dendritic cells. J Virol 80: 11899-11910.
38. Petry, H, Brooks, A, Orme, A, Wang, P, Liu, P, Xie, J et al. (2008). Effect of viral dose on neutralizing antibody response and transgene expression after AAV1 vector re-administration in mice. Gene Ther 15: 54-60.
39. Rodino-Klapac, LR, Lee, JS, Mulligan, RC, Clark, KR and Mendell, JR (2008). Lack of toxicity of α-sarcoglycan overexpression supports clinical gene transfer trial in LGMD2D. Neurology 71: 240-247.
40. Wang, B, Li, J, Qiao, C, Chen, C, Hu, P, Zhu, X et al. (2008). A canine minidystrophin is functional and therapeutic in mdx mice. Gene Ther 15: 1099-1106.
41. Brantly, ML, Chulay, JD, Wang, L, Mueller, C, Humphries, M, Spencer, LT et al. (2009). Sustained transgene expression despite T lymphocyte responses in a clinical trial of rAAV1-AAT gene therapy. Proc Natl Acad Sci USA 106: 16363-16368.
42. Gambetti, P, DiMauro, S and Baker, L (1971). Nervous system in Pompe's disease. Ultrastructure and biochemistry. J Neuropathol Exp Neurol 30: 412-430.
43. Foust, KD, Poirier, A, Pacak, CA, Mandel, RJ and Flotte, TR (2008). Neonatal intraperitoneal or intravenous injections of recombinant adeno-associated virus type 8 transduce dorsal root ganglia and lower motor neurons. Hum Gene Ther 19: 61-70.
44. Mellies, U, Stehling, F, Dohna-Schwake, C, Ragette, R, Teschler, H and Voit, T (2005). Respiratory failure in Pompe disease: treatment with noninvasive ventilation. Neurology 64: 1465-1467.
45. Pellegrini, N, Laforet, P, Orlikowski, D, Pellegrini, M, Caillaud, C, Eymard, B et al. (2005). Respiratory insuffciency and limb muscle weakness in adults with Pompe's disease. Eur Respir J 26: 1024-1031.
46. Raben, N, Nagaraju, K, Lee, E, Kessler, P, Byrne, B, Lee, L et al. (1998). Targeted disruption of the acid α-glucosidase gene in mice causes an illness with critical features of both infantile and adult human glycogen storage disease type II. J Biol Chem 273: 19086-19092.
47. DeLorme, MP and Moss, OR (2002). Pulmonary function assessment by whole-body plethysmography in restrained versus unrestrained mice. J Pharmacol Toxicol Methods 47: 1-10.
48. Drorbaugh, JE and Fenn, WO (1955). A barometric method for measuring ventilation in newborn infants. Pediatrics 16: 81-87.